EMA Recommends Granting a Marketing Authorisation for Belantamab Mafodotin By Ogkologos - August 18, 2025 314 0 Facebook Twitter Google+ Pinterest WhatsApp It is intended for the treatment of patients with relapsed or refractory multiple myeloma Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR EMA Recommends a Change to the Terms of the Marketing Authorisation... October 23, 2025 It Might Sound Trite But… May 11, 2021 Palbociclib Plus Endocrine Therapy Does Not Improve PFS over Capecitabine in... January 12, 2021 New Class of Compounds Rewires Cancer Cells to Self-Destruct August 29, 2023 Load more HOT NEWS Neoadjuvant Histotype-Tailored Treatment with Trabectedin Not Inferior to Standard Chemotherapy with... Learning to Advocate for Yourself – An Important Skill! FDA Approves Ciltacabtagene Autoleucel for Relapsed or Refractory Multiple Myeloma 31-Year-Old Mother Dies of Cancer After Her Chemotherapy Was Paused During...
